Daclatasvir,sofosbuvir (co-administered)

Form: Tablet

Strength: Daclatasvir 60 mg + Sofosbuvir 400 mg

Reference Brands: Daklinza + Sovaldi(Combo)

Category: Hepatitis

Daclatasvir and Sofosbuvir Tablets are an oral, fixed-dose combination used to treat chronic Hepatitis C infection across multiple genotypes. Daclatasvir is an NS5A inhibitor, and Sofosbuvir is an NS5B polymerase inhibitor; together, they provide a highly effective, well-tolerated antiviral regimen. Available as 60 mg Daclatasvir and 400 mg Sofosbuvir tablets, manufactured under EU-GMP and USFDA standards. Ideal for B2B licensing, hospital tenders, and global distribution with full CTD dossiers for fast registration in regulated markets.